Latest news with #572
GMA Network
4 days ago
- Climate
- GMA Network
Crising causes flooding, evacuations, 2 reported missing
Philippine Coast Guard members assist 151 residents on Friday, July 18, 2025, as they evacuate following flooding due to Tropical Storm Crising in Ilog, Negros Occidental. PCG Tropical Storm Crising brought heavy rains and caused flooding and evacuations in many areas overnight. Two people were also reported missing, according to the National Disaster Risk Reduction and Management Council (NDRRMC). Twenty-six areas were flooded in the country - two in Region 1, three in Mimaropa, two in Region 6, and nineteen in Region 7, according to NDRRMC's 6 a.m. report. Of these, flooding in two areas were reported receding. A total of 96,791 individuals or 37,598 families in 417 barangays were affected by Crising. The NDRRMC said 3,556 families or 11,689 individuals were staying in evacuation centers. Meanwhile, 1,781 families or 6,012 individuals stayed outside evacuation centers. Two people were reported missing in Region 6, to be validated by the NDRRMC. Meanwhile, as of Saturday morning, 26 roads and four bridges were not passable. A total of 1,875 individuals were stranded in various ports from 12 a.m. to 4 a.m. on Saturday, the Philippine Coast Guard (PCG) said. The PCG also said 81 vessels, 37 motorbancas, and 591 rolling cargoes were stranded. Those taking shelter meanwhile, were 57 vessels and 106 motorbancas, it added. A total of 4,595 families required assistance in Regions 1 and 6, the NDRRMC said. Total cost of assistance needed to assist the 4,595 families is P2,572,977.73. Meanwhile, 3,840 families were already assisted. —KG, GMA Integrated News
Express Tribune
6 days ago
- Business
- Express Tribune
Rupee slips 29 paisa amid import pressure
Listen to article After a brief pause, the Pakistani rupee continued its decline against the US dollar on Wednesday, falling by 0.10% in the inter-bank market amid increasing import payments, profit repatriation by multinational companies, and a cautious sentiment ahead of upcoming external debt repayments. The currency closed at 284.96, marking a depreciation of 29 paisa from Tuesday's closing rate of 284.67. This resumption of the downward trajectory follows a marginal appreciation of the rupee against the US dollar on Tuesday, when it gained 0.02%. By the end of the trading session, the rupee had closed at 284.67, up by five paisa from the previous day's close at 284.72. "The Pakistani rupee weakness stems from persistent demand for the dollar amid rising import payments, profit repatriation by multinationals, and cautious sentiment ahead of upcoming external debt repayments," said Arif Habib Ltd Deputy Head of Trading Ali Najib. In addition, the SBP is also consistently buying the US dollar from the market, taking its intervention to over $6 billion in 8MFY25, a deliberate strategy to rebuild forex reserves, driven by strong remittances, IMF funding, and debt rollover considerations, he added. Despite improving forex reserves, speculative activity and global dollar strength continue to weigh on the rupee, he said. Without stronger inflows or policy tightening, the currency is likely to face further mild depreciation in the short term. Globally, the US dollar strengthened on Wednesday alongside rising Treasury yields. The uptick followed fresh US inflation data, which suggested that President Donald Trump's renewed tariff measures may be beginning to filter into consumer prices, further pressuring currencies like the Japanese yen. Gold prices in Pakistan declined on Wednesday, in contrast to the international market, where bullion rose on the back of escalating tensions in the Middle East, tariff uncertainty, and weaker US producer price data. According to the All Pakistan Sarafa Gems and Jewellers Association, the price of gold fell by Rs3,000 per tola, settling at Rs356,000. Similarly, the rate for 10 grams dropped by Rs2,572 to Rs305,212. This follows Tuesday's decline of Rs700 per tola, when the price had closed at Rs359,000. Interactive Commodities Director Adnan Agar said the recent resurgence in global prices was tied to the revival of tariff concerns linked to Trump's trade stance. "The Trump tariff issue has resurfaced. Because of that, the market is likely to remain in this range." Agar identified strong support at $3,300, suggesting the market could range between $3,380 and $3,420 in the near term unless fresh developments alter the outlook. Globally, spot gold rose 0.2% to $3,328.14 per ounce, as of 0937 am EDT (1337 GMT). US gold futures edged 0.1% lower to $3,333.60, according to Reuters.
The Hindu
13-06-2025
- Business
- The Hindu
Garbage collection affected as contract workers continue protest in Coimbatore
Uncollected waste accumulated across multiple areas in the city on Friday as contract sanitary workers of Coimbatore Corporation continued their protest for the fifth consecutive day, disrupting regular waste collection and sanitation services in the city According to the Corporation, there are 3,442 contract sanitary workers and 525 contract drivers engaged through contractors. The civic body has stated that contract sanitation workers could be paid a maximum of ₹20,454 per month and that there was no provision to increase this amount. In a statement, the Corporation said the sanctioned net monthly salary was ₹16,000. An additional ₹1,250, compared to the previous year, was to be credited to workers' bank accounts directly by the contractor. A proposal had been sent to the Directorate of Municipal Administration seeking approval for any further increase in wages discussed during negotiations. The total monthly package includes deductions for Provident Fund (PF) and Employees' State Insurance (ESI). Of the total ₹3,750, the employer's PF contribution is ₹1,950 and the employee's ₹1,800. For ESI, the employer contributes ₹572 and the employee ₹132. These contributions are to be managed and deposited by the contractor. The Corporation also stated that salary slips would be issued by the 20th of each month. Uniforms, safety kits, reflective jackets, and gloves would be distributed. Camps would be held across wards to raise awareness among workers about PF and ESI benefits. A similar salary proposal was under consideration for Domestic Breeding Checkers (DBC). While some workers returned to duty on Friday after accepting the Corporation's terms, others continued to demand a monthly salary of ₹23,000, rejecting the ₹20,454 offered. Over 200 workers assembled at the Collectorate to press their demand and were subsequently detained by the police. 'Nearly 90% of the workers resumed duty today. We have begun clearing over 1,800 tonnes of mixed waste that had accumulated over the last four days. Segregation is under way at the Vellalore dump yard. We will continue discussions with the remaining workers who have not yet returned,' said Corporation Commissioner M. Sivaguru Prabakaran.
The Star
31-05-2025
- Politics
- The Star
Two former ministers jailed up to 25 years for graft
A court in Colombo sentenced two former ministers from the government of deposed president Gotabaya Rajapaksa on Thursday to decades in prison in a landmark corruption case. Ex-sports minister Mahindananda Aluthgamage and former trade minister Anil Fernando were found guilty by the Colombo High Court of misappropriating 53 million rupees (RM750,572) of state funds. The pair were also fined 170,870 rupees (RM8,481) for using government money to donate board games – including 14,000 carrom boards and 11,000 draughts sets – in an attempt to boost the failed 2015 re-election bid of Gotabaya's elder brother, Mahinda Rajapaksa. Aluthgamage was sentenced to 20 years in jail. Fernando was sentenced to 25 years. Aluthgamage is now the most senior member of a Rajapaksa-led Cabinet to be successfully prosecuted for corruption. The cases against both men were initiated six years ago, when the Rajapaksa brothers were out of power, but the case had been making slow headway until a new government took office last year. Aluthgamage also faces a separate investigation into allegations that he authorised in 2022 a payment of US$6.09mil to a Chinese supplier for a fertiliser shipment that was never delivered. He caused a stir in 2020 when he accused Sri Lanka's national cricket team of rigging the 2011 World Cup final in favour of India, triggering an investigation that ultimately failed to substantiate his claims. Aluthgamage, who served as sports minister from 2010 to 2015, said in June 2020 that he had 'not wanted to disclose' the alleged match-fixing plot at the time. 'In 2011, we were supposed to win, but we sold the match. I feel I can talk about it now. I am not implicating players, but certain sections were involved,' he said. — AFP
Yahoo
20-02-2025
- Business
- Yahoo
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Patent Term Adjustment will provide market exclusivity in the United States into 2040 for all therapeutic indications NEW YORK, February 20, 2025--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) that a patent will be issued covering the manufacturing methods required for the OST-HER2 commercial product. The USPTO granted a Patent Term Adjustment of 572 days, providing market exclusivity for the OST-HER2 commercial drug product into 2040. OS Therapies is preparing to initiate discussions with the United States Food & Drug Administration (FDA) following the successful treatment phase of its Phase 2b clinical trial in the prevention of recurrent, resected, lung metastatic osteosarcoma with a view towards submitting a Biologics Licensing Application (BLA) and gaining conditional or accelerated FDA approval in 2025. The Company recently completed a $7.1 million financing in January 2025 and has sufficient capital into mid-2026. OST-HER2 has already received rare pediatric disease (RPDD), fast-track (FTD) and orphan drug (ODD) designations from the US FDA for osteosarcoma. The Company intends to (1) focus on gaining FDA BLA approval for OST-HER2 in osteosarcoma in late 2025, (2) sell the Priority Review Voucher (PRV) it would receive from the FDA BLA approval prior to the September 30, 2026 PRV deadline to a larger pharmaceutical company at prevailing market prices (most recent PRV sale transaction was $150 million), (3) commercialize OST-HER2 in osteosarcoma and (4) then expand the clinical development of OST-HER2 into breast cancer and other larger solid tumor indications for additional revenue potential. OST-HER2 has successfully completed a Phase 1 trial in adult patients with HER2 overexpressing cancers, primarily breast cancer patients. Preclinical breast cancer results with OST-HER2 showed: 78% reduction in tumor size (3mm for OST-HER2 treated vs. 14mm for control arm) in FVB/N HER2 transgenic mouse model of breast cancer treatment at day 75 33% prevention of breast cancer in OST-HER2 treated mice vs. 0% prevention of breast cancer in FVB/N HER2 transgenic model of breast cancer prevention at week 50 20% reduction of tumor size for OST-HER2 plus HER2-targeted antibody vs. HER2-targeted antibody alone Tg tumor regression model of breast cancer at day 42 65% reduction cellular concentration of metastatic cells for OST-HER2-treated mice compared with controls in brain metastasis model of primary breast cancer The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research. The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases in osteosarcoma is over $500 million. The breast cancer treatment market was estimated at $29.2 billion in 2023 and expected to grow to $53.7 billion by 2030 according to Grandview Research. The Company believes the market opportunity for OST-HER2 in the treatment of breast cancer exceeds $1 billion. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received rare pediatric disease, fast-track and orphan drug designations from the US FDA. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, with positive results released in the first quarter of 2025. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's registration statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts OS Therapies Contact Information: Jack Doll571.243.9455Irpr@ Sign in to access your portfolio
